The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Use of formative evaluation surveying and tailored digital education to identify and address knowledge and competency gaps in upper tract urothelial carcinoma (UTUC) care.
 
Tariqa Ackbarali
No Relationships to Disclose
 
Wendy Turell
No Relationships to Disclose
 
Elizabeth L. del Nido
No Relationships to Disclose
 
Neal D. Shore
Consulting or Advisory Role - Abbvie; Amgen; Astellas Pharma; AstraZeneca; Bayer; Boston Scientific; Bristol-Myers Squibb/Sanofi; CG Oncology; CG Oncology; Clovis Oncology; Dendreon; Exact Imaging; Exact Sciences; FerGene; Ferring; Foundation Medicine; Genesis Cancer Care; Genzyme; Genzyme; InVitae; Janssen Scientific Affairs; MDxHealth; Medivation/Astellas; Merck; Myovant Sciences; Myriad Genetics; Nymox; Pacific Edge Biotechnology; Pfizer; Phosphorus; Propella Therapeutics; Sanofi; Sesen Bio; Tolmar; Urogen pharma
Speakers' Bureau - Astellas Pharma; AstraZeneca; Bayer; Clovis Oncology; Dendreon; Guardant Health; Janssen; Pfizer
Research Funding - Abbvie; Amgen; Astellas Pharma; AstraZeneca; Bayer; Boston Scientific; Bristol-Myers Squibb/Pfizer; Clovis Oncology; Dendreon; Exact Imaging; Ferring; Foundation Medicine; InVitae; Janssen; MDxHealth; Merck; Myovant Sciences; Myriad Genetics; Nymox; Pfizer; Sanofi; Sesen Bio; Tolmar
 
Phillip M. Pierorazio
Consulting or Advisory Role - UroGen pharma